KTE-C19用于难治性侵袭性非霍奇金淋巴瘤的ZUMA-1研究的中期分析。 - Suppr

Suppr

超能文献

An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.

作者信息

Neelapu Sattva S

机构信息

The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

出版信息

Clin Adv Hematol Oncol. 2017 Feb;15(2):117-120.

PMID:28398281

Abstract

摘要

相似文献

An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.KTE-C19用于难治性侵袭性非霍奇金淋巴瘤的ZUMA-1研究的中期分析。

Clin Adv Hematol Oncol. 2017 Feb;15(2):117-120.

The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.弥漫性大 B 细胞淋巴瘤临床试验中替代终点的探索：侵袭性淋巴瘤项目的替代终点。

Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.正电子发射断层扫描（PET）阳性非霍奇金淋巴瘤的联合治疗模式：伴有非霍奇金淋巴瘤且化疗后正电子发射断层扫描（PET）氟脱氧葡萄糖（FDG-PET）阳性的患者，采用联合治疗模式可获得良好的转归。

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

DLBCL Responds Well to Anti-CD19 CAR Therapy.弥漫性大 B 细胞淋巴瘤对抗 CD19 CAR 治疗反应良好。

Cancer Discov. 2017 Mar;7(3):241-242. doi: 10.1158/2159-8290.CD-NB2017-009. Epub 2017 Feb 2.

Management of Relapsed Diffuse Large B-cell Lymphoma.复发性弥漫性大B细胞淋巴瘤的管理

Hematol Oncol Clin North Am. 2016 Dec;30(6):1195-1213. doi: 10.1016/j.hoc.2016.07.004.

Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.自体移植用于首次复发或第二次缓解期的弥漫性侵袭性非霍奇金淋巴瘤。

Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27. doi: 10.1016/j.bbmt.2003.09.015.

Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods.在弥漫性大B细胞淋巴瘤中，中期PET上的代谢肿瘤体积比半定量方法能更好地预测预后。

Blood Cancer J. 2015 Jul 24;5(7):e326. doi: 10.1038/bcj.2015.51.

Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma.C 反应蛋白、乳酸脱氢酶和贫血对复发性或难治性侵袭性淋巴瘤的预后价值。

Jpn J Clin Oncol. 2013 Jan;43(1):37-44. doi: 10.1093/jjco/hys194. Epub 2012 Nov 19.

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.嵌合抗原受体T细胞疗法的适用性：化疗难治性弥漫性大B细胞淋巴瘤选择标准及生存结果分析

Am J Hematol. 2019 Apr;94(4):E117-E116. doi: 10.1002/ajh.25411. Epub 2019 Feb 4.

High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.高剂量疗法及自体干细胞移植治疗转化为弥漫性大B细胞淋巴瘤的滤泡性淋巴瘤

Eur J Haematol. 2008 Dec;81(6):425-31. doi: 10.1111/j.1600-0609.2008.01146.x. Epub 2008 Sep 4.

引用本文的文献

The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies.嵌合抗原受体T细胞疗法在血液系统恶性肿瘤治疗中取得的空前成功。

Cureus. 2024 May 9;16(5):e59951. doi: 10.7759/cureus.59951. eCollection 2024 May.

Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.嵌合抗原受体 T（CAR-T）细胞：血液系统恶性肿瘤的新型细胞治疗方法。

Cancer Med. 2023 Apr;12(7):7844-7858. doi: 10.1002/cam4.5551. Epub 2022 Dec 30.

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。

Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.深入了解 CAR-T 细胞疗法在非霍奇金淋巴瘤中的应用、机遇和未来方向。

Front Immunol. 2021 Jun 23;12:681984. doi: 10.3389/fimmu.2021.681984. eCollection 2021.

Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15-16 February 2019, Doha, Qatar.第一届锡德拉医学国际研讨会会议记录：“癌症免疫治疗中的工程化免疫细胞（EICCI）：从发现到现成产品开发”，2019 年 2 月 15-16 日，卡塔尔多哈。

Front Immunol. 2021 Jan 14;11:589381. doi: 10.3389/fimmu.2020.589381. eCollection 2020.

Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.CD19嵌合抗原受体T细胞治疗11例复发/难治性B细胞淋巴瘤患者的疗效和安全性：一项单中心研究

Ann Transl Med. 2020 Sep;8(17):1048. doi: 10.21037/atm-20-4363.

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.嵌合抗原受体 T 细胞在血液系统恶性肿瘤治疗中的应用。

Biomed Res Int. 2020 Oct 1;2020:4241864. doi: 10.1155/2020/4241864. eCollection 2020.

CAR T Cell Therapy for Hematological Malignancies.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤。

Curr Med Sci. 2019 Dec;39(6):874-882. doi: 10.1007/s11596-019-2118-z. Epub 2019 Dec 16.

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer.超越嵌合抗原受体T细胞：其他基于细胞的癌症免疫治疗策略

Front Oncol. 2019 Apr 10;9:196. doi: 10.3389/fonc.2019.00196. eCollection 2019.

Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.成人嵌合抗原受体 T 细胞治疗危重症患者的管理：重症监护视角。

Crit Care Med. 2018 Sep;46(9):1402-1410. doi: 10.1097/CCM.0000000000003258.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验